Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05723770 · ClinicalTrials.gov registry record · Phase 4
Effects of NOV03 on the Tear Film
A Phase 4 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT05723770 is a Phase 4 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 33 participants.
The verdict
NCT05723770, a Phase 4 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film
Interventions
- DRUG instillation of NOV03
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2023-12-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05723770
The ClinicalTrials.gov registry entry for NCT05723770 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which instillation of NOV03 is the first listed.
NCT05723770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05723770 about?
NCT05723770 is a clinical study titled "Effects of NOV03 on the Tear Film". Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film
What is the current status of trial NCT05723770?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2023-08-14. Estimated completion is 2023-12-23.
What interventions are being tested in trial NCT05723770?
The interventions under investigation include: instillation of NOV03 (DRUG).
Who is sponsoring clinical trial NCT05723770?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.